Perfuze CEO Lays Out the Challenge – and the Promise – of Buildin...

Why It Matters

Consolidation and innovation highlighted in the podcast signal accelerated competition and new growth avenues for medtech firms, making industry gatherings essential for strategic positioning.

Key Takeaways

• Device Talks Boston offers 25% discount with code DTW25.
• Danaher to acquire Massimo for $10 billion, reshaping medtech landscape.
• ResMed buying Nocttrix expands into wearable sleep‑disorder therapies.
• J&J’s Atava robot meets endpoints, entering surgical robotics market.
• Community networking at Device Talks drives collaboration and industry growth.

Summary

The latest Device Talks weekly podcast recapped the successful Minnesota gathering and turned its focus to the upcoming Device Talks Boston conference, slated for May 27‑28. Organizers highlighted a 25% early‑bird discount (code DTW25) and a packed agenda featuring keynotes, panels on Massachusetts medtech, and an expo floor designed to foster industry connections.

Beyond event promotion, the episode surveyed pivotal MedTech developments. Danaher’s $10 billion acquisition of Massimo was confirmed, signaling aggressive consolidation in digital health. ResMed announced a $340 million purchase of Nocttrix Health, extending its portfolio into wearable therapies for restless‑leg syndrome and broader sleep‑health solutions. Meanwhile, J&J reported that its Atava surgical robot met primary endpoints in a bariatric study, positioning the conglomerate for a deeper entry into the surgical robotics arena.

Hosts quoted executives and analysts to underscore the strategic relevance of these moves. Danaher’s CEO emphasized the “extra mojo” the deal brings to its diagnostics platform, while ResMed’s leadership framed the Nocttrix acquisition as a step toward becoming a comprehensive sleep‑health company. J&J’s trial success was described as a “beach‑head” for future robotic applications across specialties.

The combined narrative illustrates a medtech sector in flux: large incumbents are bolstering capabilities through high‑value M&A, while niche innovators seek scale via strategic partnerships. Industry events like Device Talks serve as crucial venues for networking, knowledge exchange, and the acceleration of these transformative trends.

Original Description

In this episode of DeviceTalks Weekly, Tom Salemi talks with Wayne Allen, the co-founder and CEO of Perfuze, an Irish company developing a novel new way of blood clot aspiration. Allen and his co-founder already executed one successful exit earlier in their careers. Can they find success again with Perfuze?

This episode is sponsored by DeviceTalks Boston. Go to Boston.DeviceTalks.com to register. Use the code DTW25 to save 25%.

MassDevice Editor Chris Newmarker opens up the podcast with this week’s top stories from the pages of MassDevice – Masimo, Danaher, ResMed, Johnson & Johnson MedTech, and Medtronic.

***

Enjoy the show? Follow [DeviceTalks Weekly](https://devicetalksweekly.castos.com/subscribe) on all major podcast players + Follow us on [YouTube.com/@DeviceTalks](https://www.youtube.com/@DeviceTalks) to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

00:02:00 Quick recap of DeviceTalks Minnesota

00:07:05 MassDevice’s Orthopedic Device Companies Special Report for 2026

00:08:20 Masimo shareholders give green light to $10B acquisition by Danaher

00:09:56 ResMed enters merger agreement to acquire Noctrix Health for $340 million

00:14:03 Johnson & Johnson says Ottava surgical robot met endpoints in pivotal bariatric surgery study

00:15:45 Medtronic merges Cardiac Surgery, Aortic units into Cardiovascular Surgery business

00:19:45 FOMO Studio – Yossi Bar, CEO, LEM Surgical

00:31:22 Keynote Interview- Wayne Allen, CEO, Perfuze